Emles at Home ETF (AMEX:LIV)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Emles at Home ETF Charts. Click Here for more Emles at Home ETF Charts.](/p.php?pid=staticchart&s=A%5ELIV&p=8&t=15)
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
innovative drugs, announced today, it is starting a second Phase II
monotherapy trial, of its lead oral entry inhibitor anti-viral agent
SP01A, in treatment experienced HIV-infected patients.
Dr. Thomas Lang, Samaritan's Chief Drug Development Officer
stated, "We have completed enrollment for our first monotherapy trial
and the start of this second trial means we have cleared another
important milestone in SP01A's development path."
Dr. Janet Greeson, CEO of Samaritan stated, "We remain
enthusiastically confident in the promise of SP01A. As we successful
complete each of these FDA milestones, it completely strengthens our
belief in SP01A as a life-saving drug for HIV drug resistant
patients."
The trial is a multi-center, double-blind, randomized,
placebo-controlled, study of orally administered SP01A as monotherapy,
in HIV-infected patients. This trial is designed to accrue
treatment-experienced HIV patients that are failing on their current
anti-viral therapy. Patients are entered into a 2-week washout phase
followed by 28 days of monotherapy treatment with SP01A. The primary
analysis for the study is the reduction in viral load (log10) in SP01A
active arms and a placebo arm, as measured from Baseline to Study-End.
For more information on this clinical trial, please go to the FDA
Clinical Trials Website at
http://www.clinicaltrial.gov/ct/show/NCT00299897?order=1
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop, and
commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer
and Heart disease. Look at www.samaritanpharma.com. Please register on
our website so we can notify you of upcoming conference calls, news
and events. http://www.samaritanpharma.com/media/signup.html
Disclaimer
The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.